DBV Technologies Reports Positive Phase 3 VITESSE Study Data for VIASKIN® Peanut Patch at AAAAI 2026 Annual Meeting

Key Highlights from the Report

• Positive Phase 3 Results: DBV Technologies announced additional positive data from its pivotal Phase 3 VITESSE trial, evaluating the VIASKIN® Peanut Patch for peanut-allergic children aged 4 to 7 years.
• Primary Endpoint Met: The study met its primary endpoint, showing a statistically significant treatment effect (p<0.001) with 46.6% of children on the VIASKIN Peanut Patch meeting responder criteria at 12 months versus 14.8% on placebo (difference: 31.8%, 95% CI: 24.5, 39.0%), surpassing the prespecified lower bound of 15%.
• Robust Secondary Data:
  • Approximately 83% of VIASKIN-treated children increased their eliciting dose at month 12, compared to 48% on placebo.
  • 60% of treated children increased their eliciting dose by at least two doses, versus 23% on placebo.
  • Only 6.4% of VIASKIN-treated children became more sensitive (decreased eliciting dose), compared to 24% on placebo.
  • All sensitivity analyses remained statistically significant, confirming robustness of the results.
  • Consistent efficacy across all baseline eliciting dose subgroups.
• Favorable Safety Profile: The majority of treatment emergent adverse events (TEAEs) were mild and localized to the patch application site, consistent with previous studies.
• Regulatory Pathway: DBV Technologies plans to submit a Biologics License Application (BLA) to the FDA in the first half of the year.

Details for Investors

• Study Significance: VITESSE is the largest food allergy immunotherapy trial to date. The results provide robust evidence supporting VIASKIN Peanut Patch as a potentially transformative, non-invasive desensitization therapy for young peanut-allergic children. The increase in eliciting dose is clinically meaningful, suggesting a reduced risk of allergic reactions in real-life accidental exposures.
• Subgroup Analyses:
  • Children with baseline eliciting dose (ED) ≤30mg: 49.3% responders with VIASKIN vs. 14.7% with placebo (Δ=34.6%; 95% CI: 24.93, 44.24).
  • Children with baseline ED = 100mg: 43.1% responders with VIASKIN vs. 14.6% with placebo (Δ=28.5%; 95% CI: 17.51, 39.5).
• Market Impact: If approved, VIASKIN® Peanut Patch would be the first non-oral immunotherapy for peanut allergy in young children, potentially securing a significant market position in pediatric allergy care.
• Regulatory and Commercial Outlook: The company is preparing for a BLA submission, a key regulatory milestone that, if successful, could lead to FDA approval and commercialization in the United States. This is a potential major catalyst for DBV Technologies’ share price.
• Company Focus: DBV Technologies is a late-stage biopharmaceutical company, developing non-invasive immunotherapy options for food allergies using its proprietary VIASKIN® patch technology. Ongoing trials include younger children (toddlers 1–3 years).
• Risks and Forward-Looking Statements: The company’s products are not yet approved for sale. There are risks associated with regulatory approval, commercial adoption, and execution of clinical and business strategies. Investors should monitor regulatory updates and upcoming data releases closely.

Potential Price-Sensitive Information

• Statistically Significant Results: The positive Phase 3 data and robust responder rates in both the overall and subgroup analyses are likely to be viewed favorably by investors and may move the share price.
• Imminent BLA Submission: The planned FDA BLA submission in the first half of the year could be a catalyst for the stock, as regulatory progress is key for late-stage biotech companies.
• Market Differentiation: VIASKIN® Peanut Patch’s non-invasive, daily-use profile could give it a significant competitive advantage in the pediatric allergy market if approved.
• Safety Profile: The consistent, mild safety profile further supports the potential for regulatory approval and broad market uptake.

Important Shareholder Considerations

• Shareholders should note the importance of the upcoming regulatory milestones and monitor for any updates regarding the FDA’s review of the BLA.
• The positive trial results and the potential for first-mover advantage in a large, unmet medical need market could have significant implications for the company’s valuation.
• As with all biotech investments, approval is not guaranteed, and there are significant risks related to future regulatory decisions and commercial adoption.

Conclusion

The additional positive data from the VITESSE Phase 3 trial further validate the clinical efficacy and safety of the VIASKIN® Peanut Patch and reinforce DBV Technologies’ position as a leader in the development of non-invasive therapies for food allergies. The imminent BLA submission to the FDA presents a major near-term catalyst for the company, with potential to unlock significant value for shareholders should approval be granted.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are subject to risks and uncertainties, including but not limited to regulatory approval and commercial adoption. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions.

View DBV Technologies S.A. Historical chart here